NCT02837588

Brief Summary

  • Treatment at pelvic floor with hyperactivity with hyperthermy electrode MJS
  • MJS electrode is effective for transvaginal treatment at pelvic pain patients
  • Hyperthermy treatment with MJS electrode is more effective to usual drugs treatment

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Aug 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2015

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

July 6, 2016

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 19, 2016

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 5, 2016

Status Verified

December 1, 2016

Enrollment Period

1.3 years

First QC Date

July 6, 2016

Last Update Submit

December 2, 2016

Conditions

Keywords

chronic pelvic paintrigger pointshiperthermy

Outcome Measures

Primary Outcomes (1)

  • NIH-CPSI questionnaire

    questions for pelvic pain evaluation

    four weeks

Secondary Outcomes (1)

  • pain measure questionnaire

    four weeks

Study Arms (2)

Hyperthermy treatment with MJS electrode

ACTIVE COMPARATOR

30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points

Device: Hyperthermy treatment with MJS electrode

CONTROL

NO INTERVENTION

No intervention with radiofrequency treatment, only evaluation to usual drug treatment

Interventions

30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points

Hyperthermy treatment with MJS electrode

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women with chronic pelvic pain

You may not qualify if:

  • chronic pelvic pain or neurological degenerative etiology
  • Presence of pathology or infectious processes genitourinary level
  • possibility of pregnancy or lactating.
  • Lack of informed consent, mental disorders, dementia, dependent people who need tutor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marta Sainz

Málaga, Málaga, 29018, Spain

Location

MeSH Terms

Conditions

Pelvic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Carolina Walker, Dr

    Universitat Central de Catalunya

    STUDY DIRECTOR
  • Marta Losa, Dr

    Universidad Rey Juan Carlos

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, coordinator of Pelvic floor department, Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

July 6, 2016

First Posted

July 19, 2016

Study Start

August 1, 2015

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

December 5, 2016

Record last verified: 2016-12

Data Sharing

IPD Sharing
Will share

It's approved from 2015 May to 2016 December, when the investigators have to report clinical trial conclusions

Locations